🇺🇸 FDA
Company

Protagonist

Protagonist Therapeutics, Inc

PTGX pharma USA

Quick answer

Protagonist is a pharma company (PTGX) headquartered in NEWARK, CA, USA with 12 tracked pipeline programs.

Pipeline (12)

project

Open-label rusfertide

Polycythemia Vera

Phase 3 · small_molecule · active

1 trials project

Placebo

Polycythemia Vera

Phase 3 · small_molecule · active

1 trials project

PN-943

Ulcerative Colitis Chronic Moderate

Phase 2 · small_molecule · completed

1 trials project

PTG-100

Ulcerative Colitis

Phase 2 · small_molecule · terminated

1 trials project

PTG-300

β-thalassemia

Phase 2 · small_molecule · completed

2 trials project

PTG-300

Hereditary Hemochromatosis

Phase 2 · small_molecule · completed

1 trials project

PTG-300

Polycythemia Vera

Phase 2 · small_molecule · completed

2 trials project

PN-232

Healthy Subjects

Phase 1 · small_molecule · completed

1 trials project

PN-235

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials project

PN-881 Oral Solution

Healthy Volunteer

Phase 1 · small_molecule · active

1 trials project

PTG-100

Celiac Disease

Phase 1 · small_molecule · completed

1 trials project

PTG-300

Healthy Volunteers

Phase 1 · small_molecule · completed

1 trials

Patents (8)

patent

US 12269856

Hepcidin analogues and uses thereof

Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12234300

Conjugated hepcidin mimetics

Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12072338

Pharmaceutical peptides for the treatment of inflammatory diseases

Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12018057

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammator

Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11939361

Compositions of peptide inhibitors of Interleukin-23 receptor

Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11884748

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflam

Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11845808

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammator

Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11840581

α4β7 thioether peptide dimer antagonists

Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)